| Literature DB >> 27672264 |
Anand Kumar1, Dharanesh Gangaiah1, Jordi B Torrelles1, Gireesh Rajashekara1.
Abstract
Campylobacter jejuni (C. jejuni), a Gram-negative microaerophilic bacterium, is a predominant cause of bacterial foodborne gastroenteritis in humans worldwide. Despite its importance as a major foodborne pathogen, our understanding of the molecular mechanisms underlying C. jejuni stress survival and pathogenesis is limited. Inorganic polyphosphate (poly P) has been shown to play significant roles in bacterial resistance to stress and virulence in many pathogenic bacteria. C. jejuni contains the complete repertoire of enzymes required for poly P metabolism. Recent work in our laboratory and others have demonstrated that poly P controls a plethora of C. jejuni properties that impact its ability to survive in the environment as well as to colonize/infect mammalian hosts. This review article summarizes the current literature on the role of poly P in C. jejuni stress survival and virulence and discusses on how poly P-related enzymes can be exploited for therapeutic/prevention purposes. Additionally, the review article identifies potential areas for future investigation that would enhance our understanding of the role of poly P in C. jejuni and other bacteria, which ultimately would facilitate design of effective therapeutic/preventive strategies to reduce not only the burden of C. jejuni-caused foodborne infections but also of other bacterial infections in humans.Entities:
Keywords: Campylobacter jejuni; Colonization/infection; Inorganic polyphosphate; Stress tolerance; Virulence
Mesh:
Substances:
Year: 2016 PMID: 27672264 PMCID: PMC5011657 DOI: 10.3748/wjg.v22.i33.7402
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Comprehensive summary of Campylobacter infections in humans
| (A) Intestinal | Periodontal diseases | Oral bleeding, increased vascular permeability[ | Oral cavity | Bleeding, tenderness, and tooth loss | |
| Esophageal diseases | Mucosal damage due to stomach contents regurgitation[ | Esophagus | Heart burn, regurgitation, bloating, bad breath, nausea, and abdominal pain | ||
| (gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma) | |||||
| Self-limited gastroenteritis, most common form | All factors as described in review | Jejunum and ileum | Diarrhea, fever, and abdominal pain | ||
| Post-infectious functional gastrointestinal disorder, irritable bowel syndrome, and functional dyspepsia | Infection with | Diarrhea, constipation or both, and abdominal pain | |||
| Inflammatory bowel disease, Crohn’s diseases (CD), and ulcerative colitis (UC) | Gut dysbiosis[ | CD-any part of intestine UC- colon | Diarrhea, fever and fatigue, abdominal pain, weight loss, and reduced appetite | ||
| Colorectal cancer | Gut dysbiosis[ | Colon | Diarrhea, constipation, abdominal pain, weight loss, and rectal bleeding | ||
| Cholecystitis | Gall stones[ | Gall bladder | Pain and tenderness in right abdomen, nausea, vomiting, and fever | ||
| (B) Extra-intestinal | Guillain-Barre syndrome | Nervous system | Progressive symmetric weakness in limbs, below or lack of reflex (hyporeflexia) | ||
| Miller Fisher syndrome | Nervous system | Oculo-motor weakness | |||
| Reactive arthritis | Infection with enteric bacterial pathogens, including | Joints, eyes, and genitourinary tract | Pain and stiffness of joints, swollen toes, eye inflammation, and urinary problems | ||
| Cardiovascular complications | Immuno-compromised condition, and bacteremia[ | Cardiovascular system | Chest pain leading to arrhythmia, dilated cardiomyopathy, and sudden death due to congestive heart failure | ||
| Meningitis | Immuno-compromised condition[ | Meninges of brain and spinal cord | Headache with nausea or vomiting, seizures, sensitive to light, and loss of appetite | ||
| Abscesses of breast, brain, vertebra, and liver | Secondary bacterial infection | Breast, brain, vertebra, and liver | Varies with target organ | ||
| Reproductive complication | Bowel infection, and periodontal disease[ | Uterus, and placenta | Preterm birth, low birth weight, and intra-uterine growth restriction |
Campylobacter infection types, clinical presentations, risk factors, target organ or tissues involved, symptoms and associated Campylobacter species are described.
Figure 1Model of poly P metabolism in Campylobacter jejuni. Phosphate esters are hydrolyzed to inorganic phosphate (Pi) by alkaline phosphatase (PhoAcj) in the periplasm. Phosphate uptake proteins and alkaline phosphatase are directly regulated by the PhosS/PhosR two-component system. Pi is transported across the inner membrane via the high affinity phosphate transport system PstSCAB. ATP generated from Pi is utilized for poly P synthesis by PPK1. PPK2 utilizes poly P to generate GTP, while PPX hydrolyzes poly P back to Pi. PPX also affects conversion of (p)ppGpp to ppGpp. SpoT is a bifunctional enzyme involved in both ppGpp synthesis as well as ppGpp hydrolysis. SpoT is also linked to poly P metabolism and a spoT mutant has reduced ability to accumulate poly P.
Phenotypes associated with enzymes of poly P and ppGpp metabolism
| Poly P metabolism | |||||||
| Poly P synthesis/accumulation | ↑ | - | - | - | - | ↑ | ↑ |
| Poly P-dependent GTP synthesis | - | ↑ | NT | NT | NT | NT | NT |
| Poly P degradation | - | - | ↑ | ↑ | ↑ | NT | NT |
| Maintenance of ATP:GTP ratio | NT | ↑ | NT | NT | NT | NT | NT |
| ppGpp metabolism | |||||||
| ppGpp synthesis | NT | - | ↑ | - | ↑ | NT | ↑ |
| Stress survival | |||||||
| Stationary phase survival and growth | - | - | - | - | - | - | ↑ |
| Survival under low CO2 | NT | NT | NT | NT | NT | NT | ↑ |
| Osmotic shock survival | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | NT |
| Low nutrient stress survival | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | NT |
| Aerobic stress survival | - | ↑ | NT | NT | NT | NT | ↑ |
| VBNC formation | ↑ | ↑ | NT | NT | NT | NT | NT |
| Natural transformation | ↑ | NT | NT | NT | NT | NT | NT |
| Antimicrobial resistance | ↑ | ↑ | NT | NT | NT | ↓ | R |
| Virulence-related | |||||||
| Motility | - | - | ↑ | ↑ | ↑ | NT | NT |
| Biofilm formation | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | NT |
| Resistance to complement-mediated killing | NT | NT | ↑ | ↑ | ↑ | NT | NT |
| Adherence | NT | - | NT | NT | NT | NT | ↑ |
| Invasion | - | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| Intraepithelial survival | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| Chicken colonization | ↑ | ↑ | NT | NT | NT | ↑ | NT |
NT: Not tested; R: Tested only for Rifampicin resistance; -: Phenotype absent; ↑: Phenotype is positively regulated i.e., deletion of the gene reduces the phenotype when compared to wildtype; ↓: Phenotype is negatively regulated i.e., deletion of the gene enhances the phenotype when compared to wildtype.
Summary of chicken colonization phenotypes of ppk1 and ppk2 mutants
| Candon et al[ | Ceca | 1.5 × 105 | 1.8 × 108 | 0/10 chicks | NS |
| 1.5 × 106 | 1.8 × 108 | 8/10 chicks | NS | ||
| 1.5 × 107 | 1.8 × 108 | 10/10 chicks at an average of 1.8 × 108 CFU/g | NS | ||
| Gangaiah et al[ | Ceca | 1.0 × 103 | 1.0 × 106 | 0/5 chicks | 0/5 chicks |
| 1.0 × 104 | 1.0 × 108 | 0/5 chicks | 0/5 chicks | ||
| 1.0 × 105 | 8.0 × 108 | 5/5 chicks at an average of 2.0 × 104 CFU/g | 5/5 chicks at an average of 9.0 × 103 CFU/g | ||
| Bursa | 1.0 × 103 | 1.0 × 104 | 0/5 chicks | 0/5 chicks | |
| 1.0 × 104 | 1.0 × 105 | 0/5 chicks | 0/5 chicks | ||
| 1.0 × 105 | 1.5 × 105 | 5/5 chicks at an average of 1.0 × 102 CFU/g | 5/5 chicks at an average of 8.0 × 102 CFU/g | ||
| Feces | 1.0 × 103 | 1.0 × 105 | 0/5 chicks | 0/5 chicks | |
| 1.0 × 104 | 1.0 × 107 | 0/5 chicks | 0/5 chicks | ||
| 1.0 × 105 | 3.0 × 107 | 5/5 chicks at an average of 1.5 × 103 CFU/g | 5/5 chicks at an average of 8.0 × 103 CFU/g |
NS: Not studied.